Literature DB >> 16421414

Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission.

Michele Cavo, Carolina Terragna, Matteo Renzulli, Elena Zamagni, Patrizia Tosi, Nicoletta Testoni, Chiara Nicci, Delia Cangini, Paola Tacchetti, Tiziana Grafone, Claudia Cellini, Michela Ceccolini, Giulia Perrone, Giovanni Martinelli, Michele Baccarani, Luciano Guardigni.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 16421414     DOI： 10.1200/JCO.2005.04.7506

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Detection of serum tumor markers in multiple myeloma using the CLINPROT system.

Authors:  Aili He; Ju Bai; Chen Huang; Juan Yang; Wanggang Zhang; Jianli Wang; Yun Yang; Pengyu Zhang; Fuling Zhou
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

2.  International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Authors:  Michele Cavo; S Vincent Rajkumar; Antonio Palumbo; Philippe Moreau; Robert Orlowski; Joan Bladé; Orhan Sezer; Heinz Ludwig; Meletios A Dimopoulos; Michel Attal; Pieter Sonneveld; Mario Boccadoro; Kenneth C Anderson; Paul G Richardson; William Bensinger; Hans E Johnsen; Nicolaus Kroeger; Gösta Gahrton; P Leif Bergsagel; David H Vesole; Hermann Einsele; Sundar Jagannath; Ruben Niesvizky; Brian G M Durie; Jesus San Miguel; Sagar Lonial
Journal:  Blood       Date:  2011-03-29       Impact factor: 22.113

3.  Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.

Authors:  S Peter Wu; Ruth M Pfeiffer; Inhye E Ahn; Sham Mailankody; Pieter Sonneveld; Mark van Duin; Nikhil C Munshi; Brian A Walker; Gareth Morgan; Ola Landgren
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

4.  Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

Authors:  N Majithia; S V Rajkumar; M Q Lacy; F K Buadi; A Dispenzieri; M A Gertz; S R Hayman; D Dingli; P Kapoor; L Hwa; J A Lust; S J Russell; R S Go; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

5.  The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Authors:  Carolina Terragna; Daniel Remondini; Marina Martello; Elena Zamagni; Lucia Pantani; Francesca Patriarca; Annalisa Pezzi; Giuseppe Levi; Massimo Offidani; Ilaria Proserpio; Giovanni De Sabbata; Paola Tacchetti; Clotilde Cangialosi; Fabrizio Ciambelli; Clara Virginia Viganò; Flores Angela Dico; Barbara Santacroce; Enrica Borsi; Annamaria Brioli; Giulia Marzocchi; Gastone Castellani; Giovanni Martinelli; Antonio Palumbo; Michele Cavo
Journal:  Oncotarget       Date:  2016-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.